Ligand Pharma (LGNZZ) Total Assets by Year
Ligand Pharma closed fiscal year 2025 with $1.6B in total assets, $543.4M in total liabilities and $1.0B in shareholder equity. This represents an increase of 65.7% from the prior fiscal year. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Ligand Pharma has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
LGNZZ Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.6B+65.7% | $941.8M+19.6% | $787.2M+3.2% | $762.7M-41.2% | $1.3B-4.7% | $1.4B-8.9% | $1.5B+18.6% | $1.3B+87.9% | $671.0M+11.5% | $601.6M+19.6% | $503.1M+95.0% | $258.0M+146.4% | $104.7M+0.4% | $104.3M-13.5% | $120.6M |
| Total Liabilities | $543.4M+388.1% | $111.3M+29.0% | $86.3M-47.8% | $165.2M-65.3% | $476.4M-27.0% | $652.8M-10.3% | $727.7M+4.0% | $699.9M+177.3% | $252.4M+9.4% | $230.7M+2.0% | $226.2M-3.2% | $233.6M+324.0% | $55.1M-29.2% | $77.8M-25.3% | $104.1M |
| Total Equity | $1.0B+22.5% | $830.4M+18.5% | $700.9M+17.3% | $597.5M-27.2% | $821.2M+15.7% | $709.5M-7.5% | $767.2M+36.8% | $560.9M+40.3% | $399.8M+17.1% | $341.3M+43.8% | $237.3M+801.6% | $26.3M-47.0% | $49.6M+87.3% | $26.5M+223.6% | $8.2M |
LGNZZ Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.2B+130.4% | $1.5B+69.2% | $1.6B+65.7% | $1.5B+54.7% | $948.6M+9.5% | $905.4M-0.9% | $941.8M+19.6% | $954.9M+24.1% | $866.4M+14.3% | $913.9M+12.7% | $787.2M+3.2% | $769.2M-26.8% |
| Total Liabilities | $1.2B+914.7% | $534.8M+386.6% | $543.4M+388.1% | $526.6M+363.2% | $120.1M+31.7% | $109.9M+2.4% | $111.3M+29.0% | $113.7M+12.2% | $91.2M-2.2% | $107.3M-34.8% | $86.3M-47.8% | $101.3M-56.8% |
| Total Equity | $967.5M+16.9% | $997.3M+25.4% | $1.0B+22.5% | $950.2M+13.0% | $827.3M+6.7% | $795.6M-1.4% | $830.4M+18.5% | $841.2M+25.9% | $775.2M+16.6% | $806.5M+24.8% | $700.9M+17.3% | $667.9M-18.2% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Ligand Pharma financials
Frequently Asked Questions
What was Ligand Pharma's total assets in fiscal year 2025?
Ligand Pharma closed fiscal year 2025 with $1.6B in total assets, $543.4M in total liabilities and $1.0B in shareholder equity.
How fast is Ligand Pharma's total assets growing?
Ligand Pharma (LGNZZ) total assets rose by 65.7% year over year, from $941.8M to $1.6B in fiscal year 2025.
How has Ligand Pharma's total assets changed over the years?
Across the 15 fiscal years this page covers, Ligand Pharma (LGNZZ) total assets went from $120.6M in fiscal year 2011 to $1.6B in fiscal year 2025.
What was Ligand Pharma's total assets in the most recent quarter?
Ligand Pharma (LGNZZ) reported $2.2B in total assets in Q2 2026. This represents an increase of 130.4% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Ligand Pharma (LGNZZ) reported on that line in every period on record.